Detalles de la búsqueda
1.
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma.
Value Health
; 26(4): 465-476, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36503035
2.
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Pharmacoecon Open
; 7(4): 567-577, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36757568
3.
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Pharmacoecon Open
; 7(2): 273-284, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36897427
4.
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.
J Comp Eff Res
; 12(8): e230004, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37431849
5.
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
J Med Econ
; 26(1): 1108-1121, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37632452
6.
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
Eur Urol Oncol
; 6(3): 339-348, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842942
7.
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Curr Med Res Opin
; 34(12): 2143-2150, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30032697
8.
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
J Manag Care Spec Pharm
; 24(6): 514-523, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29799329
9.
Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system / Tratamento baseado em imunoterapia para primeira linha do carcinoma renal avançado com risco intermediário ou alto: número necessário a tratar e custo para prevenir um evento na perspectiva do sistema privado de saúde brasileiro
J. bras. econ. saúde (Impr.)
; 13(3)2021.
Artículo
en Inglés
| LILACS, ECOS | ID: biblio-1353168
10.
Functionalized poly(γ-Glutamic Acid) fibrous scaffolds for tissue engineering.
Adv Healthc Mater
; 1(3): 308-15, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23184745
Resultados
1 -
10
de 10
1
Próxima >
>>